Nomura Holdings
MRTX

Nomura Holdings’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Nomura Holdings’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,100
Closed -$524K – 1709
2023
Q1 		$524K Buy
+14,100
New +$634K ﹤0.01% 1128

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nomura Holdings's MRTX Position: Q2 2023 in Review

Nomura Holdings sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 95,620 shares — an estimated $3.56M sold.

Nomura Holdings first reported a position in MRTX in Q2 2020 and held it in 9 quarters. The position peaked at $9.74M in Q2 2022. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Nomura Holdings reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Nomura Holdings sold 95,620 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.56M.
  • Nomura Holdings first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
  • Nomura Holdings's Mirati Therapeutics, Inc. Common Stock position peaked at $9.74M in Q2 2022.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Nomura Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.